Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
34 /100
MEDIUM RISK
Score updated Oct 13, 2026

IBRX — ImmunityBio, Inc. Dilution Risk Tracker

Track IBRX dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track IBRX — Get alerts when the score changes →

As of October 13, 2026, ImmunityBio, Inc. (IBRX) has a DilutionWatch DilutionScore of 34/100, rated MEDIUM dilution risk. ImmunityBio, Inc. has a market capitalization of $10.73B, 1.06B shares outstanding, 396 institutional holders tracked. Stored dilution-related fields include 47.86M outstanding warrants.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
26
💰 Cash Runway
40
📊 Float Risk
72
⚠️ Warrant Exposure
15
🔄 Convertible Debt
15

Dilution Forecast

☀️
Clear
No significant dilution signals
model est. 0%
No significant dilution signals detected for IBRX.
🔔 Track IBRX — Get forecast alerts →

Market Data

Market Cap$10.73B
Shares Outstanding1.06B
Float394.04M
Cash$357.37M
Debt$884.0K
Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

FieldCurrent ValueBasis
DilutionScore34/100DilutionWatch score record
Shares Outstanding1.06BVerified float table or market cache
Public Float394.04MVerified float table or market cache
Market Cap$10.73BMarket data cache
Cash Runway12.2 monthsDilutionWatch score inputs
Shelf CapacityNone in current score inputsSEC-derived dilution fields
ATM CapacityNone in current score inputsSEC-derived dilution fields
Outstanding Warrants47.86MSEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 7.

Recent SEC source mix: 4 4, SC 13D/A 1, XBRL 2.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

QoQ: ↑ 37.1% shares (2026Q1 vs prior)
396 institutional holders · 242.19M shares
#1 VANGUARD CAPITAL MANAGEMENT LLC 30.26M shares
#2 BlackRock, Inc. 26.35M shares
#3 STATE STREET CORP 17.71M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest124.09M
Days to Cover8.9
% of Float31.5%
FINRA data as of Sep 30, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2026-08-04
xbrl XBRL CONVERTIBLE 2026-02-23
4 INSIDER TRANSACTION 2026-10-06
4 INSIDER TRANSACTION 2026-10-06
SC 13D/A BENEFICIAL OWNERSHIP 2026-08-06
Full SEC filing analysis available with free account →

Recent News

Factual IBRX Dilution Snapshot

ImmunityBio, Inc. (IBRX) has a DilutionScore of 34/100, rated Medium dilution risk. Score date: October 13, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

DilutionScore History — Last 90 Days

IBRX's DilutionScore is currently 34/100 (Medium risk), with 2 score changes tracked over 89 days. The score improved from 33/100 (Medium risk).

Period Score Risk Level Duration
Sep 28 – Oct 13, 202634/100MEDIUM16 days
Sep 19 – Sep 27, 202633/100MEDIUM9 days
Jul 16 – Sep 18, 202635/100MEDIUM64 days

Score recalculated daily from SEC filings and market data. Sign up free for real-time score change alerts.

Share Dilution History

IBRX shares outstanding have increased 1.4% from 1.03B (Apr 2026) to 1.05B (May 2026). Each increase represents potential dilution to existing shareholders.

Date Shares Outstanding Public Float Change
May 12, 20261.05B394.04M▲ 2.41%
May 09, 20261.05B384.78M▲ 1.87%
Apr 15, 20261.03B377.71M▼ 1.21%
Apr 07, 20261.03B382.34M▲ 0.76%

Share counts sourced from verified regulatory filings. Increases indicate dilution events.

Track IBRX Dilution Risk in Real-Time
DilutionWatch monitors SEC filings 24/7 and alerts you the moment IBRX files a shelf registration, ATM offering, warrant notice, or convertible note. Free tier available — no credit card required.
Start Tracking IBRX — Free
Email alert within minutes of any SEC filing Daily DilutionScore™ recalculation Score history & trend tracking Tracks 8,000+ tickers simultaneously

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,490+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for IBRX
IBRX FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.